ISLATRAVIR/LENACAPAVIR
Sponsors
Gilead Sciences Inc.
Conditions
HIV-1 Infection
Phase 3
A Phase 3, Randomized, Double-Blind, Active-Controlled Study to Evaluate a Switch to an Oral Weekly Islatravir/Lenacapavir Regimen in People With HIV-1 Who Are Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir (B/F/TAF).
Active, not recruitingCTIS2024-514046-37-00
Start: 2025-01-16Target: 87Updated: 2026-01-19
A Phase 3, Randomized, Open-Label, Active-Controlled Study to Evaluate a Switch to an Oral Weekly Islatravir/Lenacapavir Regimen in People With HIV-1 Who Are Virologically Suppressed on Standard of Care
Active, not recruitingCTIS2024-514047-28-00
Start: 2025-01-27Target: 98Updated: 2025-09-12